• FDA approves testosterone self-injection for hypogonadism in men

    16 days ago - By Healio

    The FDA on Monday approved Antares Pharma's testosterone enanthate injection Xyosted for testosterone replacement therapy in men with primary hypogonadism or hypogonadotropic hypogonadism, the company announced in a press release.
    The androgen is to be administered weekly and will be available in 50-mg, 75-mg and 100-mg doses in a single-use, disposable QuickShot injection device for use at home, according to the release.
    “A once-weekly, at-home, subcutaneously administered testosterone product represents an exciting new treatment option for men suffering from hypogonadism,”
    Read more ...

     

  • FDA Clears First Testosterone Autoinjectable, Xyosted

    16 days ago - By Medscape

    Xyosted is the first self-injection testosterone replacement product for men diagnosed with conditions associated with a deficiency or absence of endogenous testosterone.
    FDA Approvals
    Read more ...